78 related articles for article (PubMed ID: 20232438)
1. Aminocarnitine ureidic derivatives as inhibitors of carnitine palmitoyltransferase I.
Tassoni E; Conti R; Gallo G; Vincenti S; Dell'Uomo N; Mastrofrancesco L; Ricciolini R; Cabri W; Carminati P; Giannessi F
ChemMedChem; 2010 May; 5(5):666-9. PubMed ID: 20232438
[No Abstract] [Full Text] [Related]
2. Derivatives of R-aminocarnitine without ammonium moiety as liver carnitine palmitoyltransferase I (L-CPT I) inhibitors.
Tassoni E; Conti R; Gallo G; Vincenti S; Mastrofrancesco L; Brunetti T; Cabri W; Giannessi F
ChemMedChem; 2011 Nov; 6(11):1977-80. PubMed ID: 21834096
[No Abstract] [Full Text] [Related]
3. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.
Giannessi F; Pessotto P; Tassoni E; Chiodi P; Conti R; De Angelis F; Dell'Uomo N; Catini R; Deias R; Tinti MO; Carminati P; Arduini A
J Med Chem; 2003 Jan; 46(2):303-9. PubMed ID: 12519067
[TBL] [Abstract][Full Text] [Related]
4. Reversible carnitine palmitoyltransferase inhibitors with broad chemical diversity as potential antidiabetic agents.
Giannessi F; Chiodi P; Marzi M; Minetti P; Pessotto P; De Angelis F; Tassoni E; Conti R; Giorgi F; Mabilia M; Dell'Uomo N; Muck S; Tinti MO; Carminati P; Arduini A
J Med Chem; 2001 Jul; 44(15):2383-6. PubMed ID: 11448219
[TBL] [Abstract][Full Text] [Related]
5. Antiketogenic and hypoglycemic effects of aminocarnitine and acylaminocarnitines.
Jenkins DL; Griffith OW
Proc Natl Acad Sci U S A; 1986 Jan; 83(2):290-4. PubMed ID: 3455765
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy.
Hülsmann WC; Peschechera A; Schneijdenberg CT; Verkleij AJ
Cardioscience; 1994 Sep; 5(3):193-7. PubMed ID: 7827256
[TBL] [Abstract][Full Text] [Related]
7. Aminocarnitine and related compounds as inhibitors of carnitine transferases: physiologic implications.
Nutr Rev; 1990 Jun; 48(6):258-60. PubMed ID: 1365754
[TBL] [Abstract][Full Text] [Related]
8. Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog.
Rufer AC; Lomize A; Benz J; Chomienne O; Thoma R; Hennig M
FEBS Lett; 2007 Jul; 581(17):3247-52. PubMed ID: 17585909
[TBL] [Abstract][Full Text] [Related]
9. The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment.
Rufer AC; Thoma R; Benz J; Stihle M; Gsell B; De Roo E; Banner DW; Mueller F; Chomienne O; Hennig M
Structure; 2006 Apr; 14(4):713-23. PubMed ID: 16615913
[TBL] [Abstract][Full Text] [Related]
10. Effects of acetyl-L-carnitine and oxfenicine on aorta stiffness in diabetic rats.
Chang KC; Tseng CD; Lu SC; Liang JT; Wu MS; Tsai MS; Hsu KL
Eur J Clin Invest; 2010 Nov; 40(11):1002-10. PubMed ID: 20678118
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and docking studies on phenoxy-3-piperazin-1-yl-propan-2-ol derivatives as protein tyrosine phosphatase 1B inhibitors.
Gupta S; Pandey G; Rahuja N; Srivastava AK; Saxena AK
Bioorg Med Chem Lett; 2010 Oct; 20(19):5732-4. PubMed ID: 20797859
[TBL] [Abstract][Full Text] [Related]
12. Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Ceccarelli SM; Chomienne O; Gubler M; Arduini A
J Med Chem; 2011 May; 54(9):3109-52. PubMed ID: 21504156
[No Abstract] [Full Text] [Related]
13. Pig muscle carnitine palmitoyltransferase I (CPTI beta), with low Km for carnitine and low sensitivity to malonyl-CoA inhibition, has kinetic characteristics similar to those of the rat liver (CPTI alpha) enzyme.
Relat J; Nicot C; Gacias M; Woldegiorgis G; Marrero PF; Haro D
Biochemistry; 2004 Oct; 43(39):12686-91. PubMed ID: 15449958
[TBL] [Abstract][Full Text] [Related]
14. Possible new therapeutic approach in diabetes mellitus by inhibition of carnitine palmitoyltransferase 1 (CPT1).
Wolf HP
Horm Metab Res Suppl; 1992; 26():62-7. PubMed ID: 1490694
[No Abstract] [Full Text] [Related]
15. Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Rupp H; Rupp TP; Maisch B
Cardiovasc Res; 2005 Jun; 66(3):423-6. PubMed ID: 15914105
[No Abstract] [Full Text] [Related]
16. Stereoisomeric acylamidomorpholinium carnitine analogues: selective inhibitors of carnitine palmitoyltransferase I and II.
Savle PS; Pande SV; Lee TS; Gandour RD
Bioorg Med Chem Lett; 1999 Nov; 9(21):3099-102. PubMed ID: 10560732
[TBL] [Abstract][Full Text] [Related]
17.
Leśniak RK; Rydzik AM; Kamps JJAG; Kahn A; Claridge TDW; Schofield CJ
Chem Commun (Camb); 2019 Dec; 55(98):14717-14720. PubMed ID: 31702759
[TBL] [Abstract][Full Text] [Related]
18. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir.
Schmitz FJ; Rösen P; Reinauer H
Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity.
Navarrete-Vazquez G; Paoli P; León-Rivera I; Villalobos-Molina R; Medina-Franco JL; Ortiz-Andrade R; Estrada-Soto S; Camici G; Diaz-Coutiño D; Gallardo-Ortiz I; Martinez-Mayorga K; Moreno-Díaz H
Bioorg Med Chem; 2009 May; 17(9):3332-41. PubMed ID: 19362487
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.
Bhattarai BR; Kafle B; Hwang JS; Khadka D; Lee SM; Kang JS; Ham SW; Han IO; Park H; Cho H
Bioorg Med Chem Lett; 2009 Nov; 19(21):6161-5. PubMed ID: 19783142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
